Vaccination during breastfeeding
First line
HPV during breastfeeding. CDC ACIP 2024 and SEGO 2023 – fully compatible. If unvaccinated before pregnancy and ≤26 (or ≤45 depending on risk) – vaccinate postpartum.
Recombinant protein vaccine, VLP
ATC code: J07BM02 (HPV nonavalent vaccine)
Contains virus-like particles (VLPs) of L1 capsid protein from nine HPV types: 6 and 11 (genital warts) and 16, 18, 31, 33, 45, 52, 58 (oncogenic). Adjuvant – aluminum hydroxyphosphate sulfate. 2-3 doses in girls 9-14, 3 doses in adults. Effectiveness against CIN 2+ cervical lesions 97%.
First line
HPV during breastfeeding. CDC ACIP 2024 and SEGO 2023 – fully compatible. If unvaccinated before pregnancy and ≤26 (or ≤45 depending on risk) – vaccinate postpartum.
Opens the checker prefilled with this drug. Pick the second one from your regimen.
Not recommended in pregnancy (defer until after delivery). Accidental vaccination is safe; no need to terminate.
Fully compatible. Hale L1.
Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.
HPV vaccine, nonavalent is evaluated for the following indications with varying evidence strength: Vaccination during breastfeeding (evidence tier A). See the full indication matrix with dosing and citations above on this page.
Common side effects of HPV vaccine, nonavalent (≥ 1 in 100): Injection-site pain (90%), Low-grade fever (10%), Headache, Fatigue. See the Safety section for uncommon and serious reactions.
FDA category B. Not recommended in pregnancy (defer until after delivery). Accidental vaccination is safe; no need to terminate.
Fully compatible. Hale L1.
HPV vaccine, nonavalent is contraindicated in: Anaphylaxis to yeast or components; Pregnancy (defer doses until after delivery); Acute febrile illness. Full list in the Safety section.